{"id":3659,"date":"2023-07-31T07:19:34","date_gmt":"2023-07-31T07:19:34","guid":{"rendered":"https:\/\/www.floridarehab.com\/?page_id=3659"},"modified":"2026-05-12T13:56:16","modified_gmt":"2026-05-12T13:56:16","slug":"withdrawal-detox","status":"publish","type":"blog","link":"https:\/\/www.floridarehab.com\/drugs\/methylphenidate\/withdrawal-detox\/","title":{"rendered":"Methylphenidate (Ritalin) Withdrawal &#038; Detox"},"content":{"rendered":"\r\n<p class=\"has-text-align-center has-large-font-size wp-block-paragraph\"><strong>A person with a methylphenidate addiction may experience withdrawal symptoms if they stop using the drug. Professional detox can help them through this process.<\/strong><\/p>\r\n<h2>Key Takeaways<\/h2>\r\n<ul>\r\n<li data-section-id=\"mjixjf\" data-start=\"913\" data-end=\"1406\">Methylphenidate withdrawal can begin within the first 12\u201324 hours after stopping or reducing use, with crash-like symptoms often strongest during days 1\u20133; symptoms such as fatigue, sleep changes, depression, anxiety, cravings and trouble concentrating may continue through the first week, and lingering mood, motivation, sleep, craving or focus problems may last into weeks 2\u20134 or longer, especially after long-term use, high-dose use, misuse or dependence (<a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"1166\" data-end=\"1229\">Li &amp; Shoptaw, 2023<\/a>; <a class=\"decorated-link\" href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"1231\" data-end=\"1404\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/a>).<\/li>\r\n<li data-section-id=\"17hiybz\" data-start=\"1408\" data-end=\"1990\">Methylphenidate is approved to treat ADHD in adults and children ages 6 and older, and some products are also approved for narcolepsy. It is sold under brand names including Ritalin, Concerta, Metadate, Methylin, Daytrana, Quillivant XR and Jornay PM (<a class=\"decorated-link\" href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a&amp;utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"2250\" data-end=\"2361\">DailyMed, 2025<\/a>; <a class=\"decorated-link\" href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"2363\" data-end=\"2451\">FDA, 2025<\/a>).<\/li>\r\n<li data-section-id=\"sl07wu\" data-start=\"3115\" data-end=\"3627\">Do not stop methylphenidate suddenly without medical guidance, especially after long-term use, high-dose use or misuse. A healthcare provider may recommend tapering or monitored dose changes to reduce withdrawal discomfort and safety risks (<a class=\"decorated-link\" href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"3362\" data-end=\"3450\">FDA, 2025<\/a>; <a class=\"decorated-link\" href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"3452\" data-end=\"3625\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/a>).<\/li>\r\n<li data-section-id=\"rcl2j\" data-start=\"3629\" data-end=\"4208\">Seek urgent medical help for severe depression, suicidal thoughts, paranoia, confusion, hallucinations, unsafe aggression, chest pain, very fast heartbeat, high fever, seizures, loss of consciousness or trouble breathing. These may signal a serious psychiatric, cardiovascular or overdose-related emergency (<a class=\"decorated-link\" href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"3943\" data-end=\"4031\">FDA, 2025<\/a>; <a class=\"decorated-link\" href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"4033\" data-end=\"4206\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/a>).<\/li>\r\n<li data-section-id=\"qauvnw\" data-start=\"4210\" data-end=\"4798\">Professional detox may be recommended when symptoms are severe, use has been heavy or long-term, cravings are strong, relapse risk is high, or co-occurring mental health symptoms are present. Treatment may include medical evaluation, symptom monitoring, tapering support when appropriate, therapy, relapse prevention planning and ongoing care (<a class=\"decorated-link\" href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"4560\" data-end=\"4733\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/a>; <a class=\"decorated-link\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/?utm_source=chatgpt.com\" target=\"_new\" rel=\"noopener\" data-start=\"4735\" data-end=\"4796\">SAMHSA, 2021<\/a>).<\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\"><span style=\"font-weight: 400;\">Methylphenidate is a prescription central nervous system stimulant used to treat attention-deficit\/hyperactivity disorder (ADHD). Some methylphenidate products are also approved to treat narcolepsy. It is sold under brand names such as Ritalin, Concerta, Metadate, Methylin, Daytrana, Quillivant XR and Jornay PM (<\/span><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">DailyMed, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> U.S. Food and Drug Administration (FDA), 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">When taken in higher doses than prescribed, used without a prescription or misused in other ways, methylphenidate can increase the risk of dependence, addiction and withdrawal. FDA labeling for methylphenidate products warns that central nervous system stimulants have a high potential for abuse and misuse, which can lead to substance use disorder, including addiction. Misuse and abuse can also increase the risk of overdose and death (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Withdrawal can affect mood, energy, sleep, appetite and concentration. Professional detox and treatment can help people manage symptoms, reduce relapse risk and begin recovery when misuse, dependence or stimulant use disorder is present (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Methylphenidate Duration and Withdrawal Timeline<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">The duration of methylphenidate\u2019s effects depends on the formulation. Immediate-release methylphenidate typically has a shorter duration of action, while extended-release products, such as Concerta, are designed to provide symptom control for a longer period of the day (<\/span><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">DailyMed, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">A person dependent on methylphenidate may start to feel withdrawal symptoms as the drug wears off or after stopping use. Stimulant withdrawal symptoms can develop during early abstinence and may include fatigue, mood changes, sleep changes, increased appetite and cravings (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">The complete methylphenidate withdrawal timeline will vary based on the person and the extent of use. Symptoms may last several days to weeks, and some people may experience lingering mood, sleep or craving-related symptoms for longer. People who have used methylphenidate for a long time, at high doses or in ways not prescribed may experience more severe or persistent symptoms (<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<p><b>Timeframe<\/b><\/p>\r\n<\/td>\r\n<td>\r\n<p><b>What May Happen<\/b><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">First 12\u201324 hours<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Early effects may begin as the medication wears off, including fatigue, irritability, cravings, increased appetite or trouble concentrating.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Days 1\u20133<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Some people experience a crash, with low energy, increased sleep, mood changes, depression or strong cravings.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Week 1<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Sleep changes, low mood, restlessness and concentration problems may continue.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Weeks 2 and beyond<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Some people may experience lingering depression, cravings, sleep issues or difficulty focusing.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<h2><b>Why Do People Misuse This Medication?<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Misuse happens when someone takes the medication in a way other than prescribed. This may include taking higher doses, taking it more often, using someone else\u2019s prescription or changing the form of the medication to intensify its effects. FDA labeling warns that misuse and abuse of methylphenidate can involve higher doses or unapproved routes of administration, such as snorting or injection, which can increase the risk of overdose and death (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Some people misuse methylphenidate to stay awake longer, improve focus, increase energy, suppress appetite, feel more productive or experience a high. A recent AHRQ evidence review reported that common reasons for adult prescription stimulant misuse include helping concentration, staying alert or awake, studying, losing weight and getting high or partying (<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK620122\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Maglione et al., 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Over time, misuse can increase tolerance and make a person feel like they need the drug to function, study, work or feel normal. FDA labeling states that methylphenidate may produce tolerance and physical dependence, and clinical guidance recognizes craving and compulsive use patterns as important features of stimulant use disorder (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>What Is Methylphenidate Withdrawal?<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Methylphenidate withdrawal is a type of stimulant withdrawal that can occur when someone who has been using the medication regularly stops taking it or significantly reduces their dose. Over time, the brain and body can adapt to the medication\u2019s effects. When the drug is removed, the body needs time to readjust (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Withdrawal symptoms may be more likely or more severe when a person has used high doses, misused the <a href=\"https:\/\/www.floridarehab.com\/treatment\/medication-assisted-treatment\/\">medication<\/a>, taken it for a long time or developed dependence. People should speak with a healthcare provider before stopping methylphenidate, especially after high-dose, long-term or non-prescribed use (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Ritalin Withdrawal and Tapering<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Ritalin is a brand name for methylphenidate. Ritalin withdrawal refers to the effects that can happen after someone stops or reduces this medication, especially after long-term use, high-dose use or misuse. Ritalin labeling identifies it as a central nervous system stimulant used for ADHD in adults and children ages 6 and older, as well as narcolepsy (<\/span><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">DailyMed, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">These effects may include fatigue, excessive sleepiness, depression, irritability, cravings, increased appetite, sleep changes and difficulty concentrating. FDA labeling for methylphenidate products states that withdrawal signs and symptoms after abrupt discontinuation or significant dose reduction following prolonged use of central nervous system stimulants can include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite and psychomotor retardation or agitation (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">The experience can vary depending on the dose, formulation, length of use, whether the medication was misused and whether the person stops suddenly. People should not stop or change their dose without medical guidance. A healthcare provider may recommend tapering, which involves gradually reducing the dose to help the body adjust and reduce discomfort (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Crash vs. Withdrawal Symptoms<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">A crash can happen as the effects of methylphenidate wear off between doses or after use. Withdrawal is more likely after regular, heavy or dependent use is stopped or reduced. Stimulant withdrawal symptoms may include changes in mood, energy, appetite, sleep and psychomotor activity (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<p><b>Crash<\/b><\/p>\r\n<\/td>\r\n<td>\r\n<p><b>Withdrawal<\/b><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Can happen as a dose wears off<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Can happen after stopping or reducing use<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">May last hours to a day<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">May last several days to weeks<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Often includes fatigue, irritability, low mood or increased appetite<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">May include fatigue, depression, cravings, sleep changes and trouble concentrating<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Can happen even with prescribed use<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">More likely with dependence, misuse, high doses or long-term use<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Usually improves as the body recovers from the dose wearing off<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">May require medical guidance, detox or treatment support<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<p><span style=\"font-weight: 400;\">A crash is usually shorter, while withdrawal may last longer and may involve stronger cravings, mood changes or relapse risk (<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Signs and Symptoms<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Withdrawal can affect both physical and psychological health. Symptoms may vary based on dose, length of use, frequency of use, health history and whether the drug is stopped suddenly (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Common withdrawal symptoms may include:<\/span><\/p>\r\n<ul>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Fatigue<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Excessive sleepiness<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Sleep disturbances<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Increased appetite or hunger<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Trouble concentrating<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.floridarehab.com\/co-occurring-disorders\/anxiety-disorders\/\"><span style=\"font-weight: 400;\">Anxiety<\/span><\/a><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><a href=\"https:\/\/www.floridarehab.com\/co-occurring-disorders\/depression\/\"><span style=\"font-weight: 400;\">Depression<\/span><\/a><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Irritability<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Mood swings<\/span><\/li>\r\n<li aria-level=\"1\"><a href=\"https:\/\/www.floridarehab.com\/co-occurring-disorders\/psychosis\/\">Psychosis<\/a><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cravings<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Agitation or aggression<\/span><\/li>\r\n<\/ul>\r\n<p><span style=\"font-weight: 400;\">FDA labeling for methylphenidate products specifically identifies withdrawal symptoms such as dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite and psychomotor slowing or agitation after abrupt discontinuation or significant dose reduction following prolonged use (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Some symptoms can signal a more serious reaction and should not be ignored. Seek urgent support if symptoms include suicidal thoughts, severe depression, paranoia, confusion, unsafe aggression or symptoms that are getting worse instead of improving. Clinical guidelines for stimulant use disorder emphasize monitoring and treating serious psychiatric symptoms, including psychosis, agitation and suicidality, when they occur (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>What Affects Severity?<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Several factors can affect how intense symptoms feel and how long they last. These include the dose, length of use, frequency of use, misuse, co-occurring mental health conditions, abrupt discontinuation and other substance use (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<table>\r\n<tbody>\r\n<tr>\r\n<td>\r\n<p><b>Factor<\/b><\/p>\r\n<\/td>\r\n<td>\r\n<p><b>How It Can Affect the Process<\/b><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Dose<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Higher doses may increase the risk of stronger symptoms.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Length of use<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Long-term use may make it harder for the body to adjust.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Frequency of use<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">More frequent use may increase the likelihood of dependence.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Misuse<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Taking the drug in ways not prescribed can increase risks.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Mental health history<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Depression, anxiety, ADHD or other concerns may complicate treatment.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Stopping suddenly<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Abrupt changes may make symptoms harder to manage.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<tr>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Other substance use<\/span><\/p>\r\n<\/td>\r\n<td>\r\n<p><span style=\"font-weight: 400;\">Alcohol, drugs or other medications may affect safety and symptom severity.<\/span><\/p>\r\n<\/td>\r\n<\/tr>\r\n<\/tbody>\r\n<\/table>\r\n<h2><b>Signs of Addiction<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Addiction, also called a substance use disorder, can develop when a person continues using the drug despite harmful effects. Only a qualified healthcare professional can diagnose this condition, but certain signs may suggest that help is needed. FDA labeling warns that methylphenidate has a high potential for abuse and misuse, which can lead to substance use disorder, including addiction (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Possible signs include:<\/span><\/p>\r\n<ul>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Taking more than prescribed<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Using the drug without a prescription<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Trying to cut down but being unable to stop<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Cravings<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Spending a lot of time getting, using or recovering from the drug<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Falling behind at work, school or home because of use<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Continuing to use despite sleep problems, mood changes or health issues<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Needing higher doses to feel the same effects<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Feeling unwell when stopping or reducing use<\/span><\/li>\r\n<\/ul>\r\n<p><span style=\"font-weight: 400;\">These signs are consistent with core features of substance use disorders, including impaired control, craving, continued use despite harm, tolerance and withdrawal (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Safety Risks and Emergency Warning Signs<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Taking too much methylphenidate or combining it with other substances can increase the risk of serious harm, including overdose. FDA labeling warns that misuse and abuse of methylphenidate can result in overdose and death, and that the risk is increased with higher doses or unapproved methods of administration (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Emergency care may be needed if someone has chest pain, a very fast heartbeat, high fever, seizures, hallucinations, severe agitation, loss of consciousness or trouble breathing. Methylphenidate overdose may involve cardiovascular, neurological and psychiatric complications, and severe stimulant-related symptoms require urgent medical evaluation (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Medical help is also important if withdrawal feels overwhelming, unsafe or difficult to manage. Professional support is especially important for people who have taken high doses, misused the medication or have a history of severe depression, psychosis or suicidal thoughts (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Methylphenidate Detox and Treatment<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Treatment should be guided by a medical professional when symptoms are severe, use has been heavy or long-term, or there are concerns about addiction. Clinical guidelines for stimulant use disorder recommend comprehensive assessment, withdrawal management, treatment of co-occurring conditions and linkage to ongoing care (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Professional drug detox may be recommended for people with severe symptoms, long-term misuse, strong cravings, co-occurring mental health concerns or a high risk of relapse. During detox, medical professionals may monitor mood, sleep, appetite and safety while helping manage complications such as depression, insomnia, agitation or cravings (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">In some cases, clinicians may use medications to help manage specific withdrawal-related symptoms or co-occurring psychiatric symptoms. However, medication decisions should always be handled by a medical professional, and there is no single FDA-approved medication that treats every aspect of stimulant withdrawal or stimulant use disorder (<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> Substance Abuse and Mental Health Services Administration (SAMHSA), 2021<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">A treatment plan may also include:<\/span><\/p>\r\n<ul>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Medical evaluation<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Tapering support when appropriate<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Symptom monitoring<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Mental health support<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Therapy or counseling<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Relapse prevention planning<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Support for co-occurring disorders<\/span><\/li>\r\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Transition into ongoing addiction treatment<\/span><\/li>\r\n<\/ul>\r\n<p><span style=\"font-weight: 400;\">Detox can help a person get through the early stage of stopping, but it is not the same as full treatment. Ongoing treatment may be needed to address cravings, triggers, co-occurring conditions and relapse risk. For some people, addiction treatment may include multiple levels of care, such as detox, residential treatment, outpatient treatment and continuing recovery support (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> SAMHSA, 2021<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Once the detox process has begun, the person may be offered a variety of other <a href=\"https:\/\/www.floridarehab.com\/drugs\/methylphenidate\/treatment-rehab\/\">treatment forms<\/a>, including group counseling, family counseling and <a href=\"https:\/\/www.floridarehab.com\/treatment\/addiction-therapies\/cognitive-behavioral\/\">cognitive behavioral therapy<\/a>. Cognitive behavioral therapy can help people identify thoughts, behaviors, triggers or underlying issues that may contribute to methylphenidate misuse. Evidence-based behavioral treatments for stimulant use disorders include contingency management, cognitive behavioral therapy, community reinforcement and motivational interviewing (<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">SAMHSA, 2021<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">The goal of treatment is to help the person stabilize, understand what contributed to misuse and build a safer plan for recovery. Treatment may also address co-occurring ADHD, depression, anxiety or other concerns that can affect relapse risk (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> SAMHSA, 2021<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Medication decisions should always be handled by a medical professional. Pharmacological support may be considered in some cases, but there is no single medication that treats every aspect of this process (<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> SAMHSA, 2021<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>Counseling and Recovery Support<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">Therapy can help people understand why misuse developed and build healthier coping skills. This may be especially helpful for people with attention concerns, depression or other co-occurring issues. Clinical guidance for stimulant use disorder emphasizes behavioral treatment, co-occurring disorder care and continuing support as part of recovery (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> SAMHSA, 2021<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<p><span style=\"font-weight: 400;\">Treatment may include cognitive behavioral therapy, individual counseling, group sessions or family support. These services may help people identify triggers, manage cravings, build coping skills, improve relapse prevention strategies and strengthen support systems (<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">SAMHSA, 2021<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n\r\n\r\n\r\n<h2 class=\"wp-block-heading\">Methylphenidate Detox Programs and Treatment Centers<\/h2>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">The best way to successfully detox from methylphenidate is to get help. Treatment centers can provide supervision and medical help during the\u00a0<a href=\"https:\/\/www.floridarehab.com\/treatment\/medical-detox\/\">detoxification process<\/a>\u00a0to make sure the individual stays as comfortable as possible.<\/p>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">If you or a loved one struggle with a substance use disorder, The Recovery Village Palm Beach at Baptist Health can help. A professional addiction treatment facility can help people address their addiction and any co-occurring mental health disorders.\u00a0<a href=\"https:\/\/www.floridarehab.com\/contact-us\/\">Contact The Recovery Village Palm Beach at Baptist Health<\/a>\u00a0to speak to a representative about taking the first step toward a healthier future.<\/p>\r\n<h2><b>FAQs<\/b><\/h2>\r\n<h3><b>Can methylphenidate withdrawal cause depression?<\/b><\/h3>\r\n<p><span style=\"font-weight: 400;\">Yes. Some people may experience depression, low motivation or emotional flatness after stopping. FDA labeling for methylphenidate products lists dysphoric mood and depression among possible withdrawal symptoms after abrupt discontinuation or significant dose reduction following prolonged use of central nervous system stimulants (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">). In some cases, stopping may also reveal an underlying mood disorder. Severe depression or suicidal thoughts require immediate medical help (<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h3><b>Can methylphenidate withdrawal cause cravings?<\/b><\/h3>\r\n<p><span style=\"font-weight: 400;\">Yes. Cravings can happen, especially if the drug was misused or taken for a long time. Cravings can increase relapse risk, so professional support may be helpful. Clinical reviews of psychostimulant withdrawal describe craving as a common and clinically important withdrawal-related concern (<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Li &amp; Shoptaw, 2023<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h3><b>Can you stop methylphenidate suddenly?<\/b><\/h3>\r\n<p><span style=\"font-weight: 400;\">People should speak with a healthcare provider before stopping methylphenidate, especially after long-term use, high-dose use or misuse. FDA labeling states that withdrawal signs and symptoms can occur after abrupt discontinuation or significant dose reduction following prolonged use of central nervous system stimulants. Tapering or monitored dose changes can help the body adjust more gradually when clinically appropriate (<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">FDA, 2025<\/span><\/a><span style=\"font-weight: 400;\">;<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee, 2024<\/span><\/a><span style=\"font-weight: 400;\">).<\/span><\/p>\r\n<h2><b>References<\/b><\/h2>\r\n<p><span style=\"font-weight: 400;\">ASAM\/AAAP Clinical Guideline Committee. (2024). <\/span><i><span style=\"font-weight: 400;\">The ASAM\/AAAP clinical practice guideline on the management of stimulant use disorder<\/span><\/i><span style=\"font-weight: 400;\">. <\/span><i><span style=\"font-weight: 400;\">Journal of Addiction Medicine, 18<\/span><\/i><span style=\"font-weight: 400;\">(1), 1\u201356.<\/span><a href=\"https:\/\/doi.org\/10.1097\/ADM.0000000000001299\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">https:\/\/doi.org\/10.1097\/ADM.0000000000001299<\/span><span style=\"font-weight: 400;\"><br \/><\/span><\/a><span style=\"font-weight: 400;\"> Full hyperlink:<\/span><a href=\"https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx\" target=\"_blank\" rel=\"noopener\"> <span style=\"font-weight: 400;\">https:\/\/journals.lww.com\/journaladdictionmedicine\/fulltext\/2024\/05001\/the_asam_aaap_clinical_practice_guideline_on_the.1.aspx<\/span><\/a><\/p>\r\n<p><span style=\"font-weight: 400;\">DailyMed. (2025). <\/span><i><span style=\"font-weight: 400;\">Ritalin\u2014methylphenidate hydrochloride tablet<\/span><\/i><span style=\"font-weight: 400;\">. National Library of Medicine.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\"> Full hyperlink:<\/span><a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a<\/span><\/a><\/p>\r\n<p><span style=\"font-weight: 400;\">Li, M. J., &amp; Shoptaw, S. J. (2023). Clinical management of psychostimulant withdrawal: Review of the evidence. <\/span><i><span style=\"font-weight: 400;\">Addiction, 118<\/span><\/i><span style=\"font-weight: 400;\">(4), 750\u2013762. https:\/\/doi.org\/10.1111\/add.16093<\/span><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\"> Full hyperlink:<\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> https:\/\/pubmed.ncbi.nlm.nih.gov\/36401591\/<\/span><\/a><\/p>\r\n<p><span style=\"font-weight: 400;\">Maglione, M., Raaen, L., Chen, C., Borsky, A. E., Motala, A., Hempel, S., Booth, M., &amp; Rouse, B. (2025). <\/span><i><span style=\"font-weight: 400;\">Misuse of ADHD prescription stimulants in adults<\/span><\/i><span style=\"font-weight: 400;\">. Agency for Healthcare Research and Quality.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\"> Full hyperlink:<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK620122\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK620122\/<\/span><\/a><\/p>\r\n<p><span style=\"font-weight: 400;\">Substance Abuse and Mental Health Services Administration. (2021). <\/span><i><span style=\"font-weight: 400;\">Treatment for stimulant use disorders<\/span><\/i><span style=\"font-weight: 400;\"> (Treatment Improvement Protocol [TIP] Series, No. 33; SAMHSA Publication No. PEP21-02-01-004). U.S. Department of Health and Human Services.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\"> Full hyperlink:<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576541\/<\/span><\/a><\/p>\r\n<p><span style=\"font-weight: 400;\">U.S. Food and Drug Administration. (2025). <\/span><i><span style=\"font-weight: 400;\">Concerta\u00ae (methylphenidate hydrochloride) extended-release tablets prescribing information<\/span><\/i><span style=\"font-weight: 400;\">.<\/span><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\"> Full hyperlink:<\/span><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\"> https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/021121s053lbl.pdf<\/span><\/a><\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>A person with a methylphenidate addiction may experience withdrawal symptoms if they stop using the drug. Professional detox can help them through this process. Key Takeaways Methylphenidate withdrawal can begin within the first 12\u201324 hours after stopping or reducing use, with crash-like symptoms often strongest during days 1\u20133; symptoms such as fatigue, sleep changes, depression, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":3647,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"categories":[],"tags":[],"class_list":["post-3659","blog","type-blog","status-publish","hentry"],"acf":{"written_by":317,"enable_medically_and_up":["Yes"],"medically_reviewed_by":313,"medically_reviewed_content":"This article was reviewed by a medical professional to guarantee the delivery of accurate and up-to- date information. <a href=\"\/research\/\">View our research policy.<\/a>","up_to_date":"<i>Last Updated<\/i> - <b>07\/15\/2020<\/b>","page_first_published_date":"20200715","page_last_edit_date":"20200715","highlighted_description":"If you or a loved one is struggling with addiction, help is available. Speak with a Recovery Advocate by calling <a href=\"tel:8886480738\"><b>888-648-0738<\/b><\/a> now.","key_takeaways":"","source":{"source_label":"View Sources","source_content":"Food and Drug Administration. \u201c<a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/010187s077lbl.pdf\" target=\"_blank\" rel=\"noopener\">Ritalin<\/a>.\u201d Accessed July 25, 2019.\r\n\r\nNational Institute of Drug Abuse. \u201c<a href=\"https:\/\/www.drugabuse.gov\/publications\/drugfacts\/prescription-stimulants\" target=\"_blank\" rel=\"noopener\">Prescription Stimulants<\/a>.\u201d June 2018. Accessed July 25, 2019."},"staff_member_heading":"Authorship","staff_member":[{"staff_member_title":"Editor","select_staff_member":317},{"staff_member_title":"Medical Reviewer","select_staff_member":313}],"insurance_label":""},"_links":{"self":[{"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/blog\/3659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/blog"}],"about":[{"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/types\/blog"}],"author":[{"embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/comments?post=3659"}],"version-history":[{"count":0,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/blog\/3659\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/blog\/3647"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/staff\/313"},{"embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/staff\/317"}],"wp:attachment":[{"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/media?parent=3659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/categories?post=3659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.floridarehab.com\/wp-json\/wp\/v2\/tags?post=3659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}